5th European Congress: Perspectives in Gynecologic Oncology

Last Modified: October 12, 2007

Conference Dates: January 18-19, 2008
Conference Location: Cannes, France

Sponsoring Group: Schering-Plough

Conference Web Page URL: www.imedex.com/announcements/317.asp

Topics Covered: Cervical Cancer Endometrial Cancer and Vulvar Cancer Ovarian Neoplasm I Ovarian Neoplasm II

Conference Objectives: Assess the impact of recently available HPV vaccines on the prevention and screening of cervical cancer. Develop a practical, case-based approach to management of early-stage cervical cancer and advanced disease. Apply advances and strategies in staging and management of endometrial cancer to clinical practice. Derive the optimal surgical management of ovarian cancer based on disease stage and clinical presentation. Formulate the best management strategies for recurrent ovarian cancer. Indentify emerging therapies for gynecologic cancers, and develop strategiesto integrate them into current disease management.

Who Should Attend: gynecologists, oncologists, radiation therapists, pathologists and other pracitioners involved in the diagnosis and management of gynecologic cancers including ovarian, endometrial and cervical cancers. For physicians, nurses, residents and students.

Conference Agenda: Friday, January 18, 2008 Session I: Cervical Cancer Session II: Endometrial Cancer and Vulvar Cancer, Saturday, January 19, 2008 Session III: Ovarian Neoplasm I Keynote Address - Emerging targeted therapies for ovarian cancer Session IV: Ovarian Neoplasm II

Registration Information: 4 Easy Ways to Register 1. Online: www.imedex.com 2. Call us: +1(678)242 0906 3. Fax us: +1(678)242 0920 4. Mail us: 4325 Alexander Dr., Alpharetta, GA 30040-3740, USA

Conference Fees: Discounted $352.00- Regular $493- Onsite $634- Nurses, Residents, Students $140

Continuing Education: Yes


Where Are the Adults in the Room?
by Rodney Warner, JD
November 20, 2015

Related News

More Evidence Daily Aspirin May Protect Against GI Cancer

Sep 30, 2015

Four-year study found survival doubled for GI cancer patients who took low-dose pill each day

Novel Immunotx Shows Promise Against Advanced Renal Cancer

Nov 25, 2015

Nivolumab appears to outperform everolimus in new clinical trial

Impact of Prenatal Exposure to Maternal Cancer Explored

Sep 28, 2015

Prenatal exposure to maternal cancer, with or without tx, doesn't impact early child development